Literature DB >> 10331931

Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group.

R H Hunt1, C A Fallone, A B Thomson.   

Abstract

The first Canadian Helicobacter pylori Consensus Conference took place in April 1997. The initial recommendations of the conference were published in early 1998. An update meeting was held in June 1998, and the present paper updates and complements the earlier recommendations. Key changes included the following: the recommendation for testing and treating H pylori infection in patients with known peptic ulcer disease was extended to testing and treating patients with ulcer-like dyspepsia; it was decided that the urea breath test (not serology) should be used for routine diagnosis of H pylori infection unless endoscopy is indicated for another reason; and recommended therapies were a twice daily, seven-day regimen of a proton pump inhibitor (omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg) or ranitidine bismuth citrate 400 mg, plus clarithromycin 500 mg and amoxicillin 1000 mg, or plus clarithromycin 500 or 250 mg and metronidazole 500 mg. The need was reiterated to have funding for readily accessible, accurate testing for H pylori infection with the urea breath test. It was strongly recommended that regional centres be established to monitor the prevalence of antibiotic-resistant H pylori infections. The initial consensus document referred to pediatric issues that were not addressed in this update but were the subject of a subsequent Canadian Helicobacter Study Group meeting, and will be published later in 1999.

Entities:  

Mesh:

Year:  1999        PMID: 10331931     DOI: 10.1155/1999/180751

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  21 in total

Review 1.  The urea breath test for Helicobacter pylori infection: taking the wind out of the sails of endoscopy.

Authors:  C A Fallone; S J Veldhuyzen van Zanten; N Chiba
Journal:  CMAJ       Date:  2000-02-08       Impact factor: 8.262

2.  Concerns about the critical appraisal of the role of H pylori in dyspepsia.

Authors:  N Chiba; S J Veldhuyzen van Zanten
Journal:  Can Fam Physician       Date:  2000-09       Impact factor: 3.275

3.  AAPS/RAPS/CAPRA collaborative program: exploring the challenges of drug regulation in a global environment: clinical concerns.

Authors:  Marilyn N Martinez; Iain McGilveray
Journal:  AAPS PharmSci       Date:  2003-10-23

Review 4.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

5.  13C urea breath test for (Helicobacter pylori): evaluation of 10-minute breath collection.

Authors:  Marina Mauro; Vladimir Radovic; Melanie Wolfe; Markad Kamath; Premsyl Bercik; David Armstrong
Journal:  Can J Gastroenterol       Date:  2006-12       Impact factor: 3.522

6.  Helicobacter pylori and antibiotic resistance.

Authors:  Francis Megraud
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

7.  Natural course of functional dyspepsia after Helicobacter pylori eradication: a seven-year survey.

Authors:  Francesco di Mario; Nicoletta Stefani; Nadia Dal Bò; Massimo Rugge; Alberto Pilotto; Giulia Martina Cavestro; Lucas Giovanni Cavallaro; Angelo Franzé; Gioacchino Leandro
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

8.  13C urea breath test for (Helicobacter pylori): determination of the optimal cut-off point in a Canadian community population.

Authors:  Marina Mauro; Vladimir Radovic; Pengfei Zhou; Melanie Wolfe; Markad Kamath; Premsyl Bercik; Ken Croitoru; David Armstrong
Journal:  Can J Gastroenterol       Date:  2006-12       Impact factor: 3.522

Review 9.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Basis for the management of drug-resistant Helicobacter pylori infection.

Authors:  Francis Mégraud
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.